2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis

European Respiratory Journal

Volumn 48, Issue 3, 2016, Pages 768-779

  Vijftigschild, Lodewijk A W ^a   Berkers, Gitte ^a   Dekkers, Johanna F ^a   Zomer Van Ommen, Domenique D ^a   Matthes, Elizabeth ^b   Kruisselbrink, Evelien ^a   Vonk, Annelotte ^a   Hensen, Chantal E ^a   Heida Michel, Sabine ^a   Geerdink, Margot ^a   Janssens, Hettie M ^c   Van De Graaf, Eduard A ^a   Bronsveld, Inez ^a   De Winter De Groot, Karin M ^a   Majoor, Christof J ^d   Heijerman, Harry G M ^e   De Jonge, Hugo R ^f   Hanrahan, John W ^b   Van Der Ent, Cornelis K ^a   Beekman, Jeffrey M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MCGILL UNIVERSITY   (Canada)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e HAGA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOPAMINE; EPINEPHRINE; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; IVACAFTOR; LUMACAFTOR; RITODRINE; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CFTR PROTEIN, HUMAN; CHLORIDE;

ADULT; AIRWAY EPITHELIAL CELL; ARTICLE; CFTR GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; CYTOPLASM; DRUG POTENCY; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; BIOASSAY; BRONCHUS; CELL CULTURE; CELL LINE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; EPITHELIUM; EPITHELIUM CELL; GENETICS; METABOLISM; MUTATION; ORAL DRUG ADMINISTRATION; ORGANOID; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; BIOLOGICAL ASSAY; BRONCHI; CELL LINE; CELLS, CULTURED; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; EPITHELIUM; HUMANS; MUTATION; NASAL MUCOSA; ORGANOIDS; PILOT PROJECTS; RESPIRATORY SYSTEM; SIGNAL TRANSDUCTION;

EID: 84986199922     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01661-2015     Document Type: Article

References (40)

1. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-726.
2. Weiler CA, Drumm ML. Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol 2013; 4: 40.
3. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 1036-1043.
4. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45: 1160-1167.
5. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (delta F508). N Engl J Med 1990; 323: 1517-1522.
6. Castellani C, Cuppens H, Macek M, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7: 179-196.
7. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67: 117-133.
8. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825-18830.
9. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
10. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991-2003.
11. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220-231.
12. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108: 18843-18848.
13. Chan HC, Fong SK, So SC, et al. Stimulation of anion secretion by beta-adrenoceptors in the mouse endometrial epithelium. J Physiol 1997; 501: 517-525.
14. Smith JJ, Welsh MJ. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. J Clin Invest 1992; 89: 1148-1153.
15. Waldman DB, Gardner JD, Zfass AM, et al. Effects of vasoactive intestinal peptide, secretin, and related peptides on rat colonic transport and adenylate cyclase activity. Gastroenterology 1977; 73: 518-523.
16. Jung P, Sato T, Merlos-Suárez A, et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011; 17: 1225-1227.
17. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013; 340: 1190-1194.
18. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
19. Dekkers JF, van der Ent CK, Beekman JM. Novel opportunities for CFTR-targeting drug development using organoids. Rare Dis 2013; 1: e27112.
20. Dekkers JF, Wiegerinck CL, de Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19: 939-945.
21. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.
22. de Lau W, Barker N, Low TY, et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011; 476: 293-297.
23. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997; 275: 1784-1787.
24. Bruscia E, Sangiuolo F, Sinibaldi P, et al. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther 2002; 9: 683-685.
25. Swiatecka-Urban A, Moreau-Marquis S, Maceachran DP, et al. Pseudomonas aeruginosa inhibits endocytic recycling of CFTR in polarized human airway epithelial cells. Am J Physiol Cell Physiol 2006; 290: C862-C872.
26. Vijftigschild LA, van der Ent CK, Beekman JM. A novel fluorescent sensor for measurement of CFTR function by flow cytometry. Cytometry A 2013; 83: 576-584.
27. Robert R, Carlile GW, Liao J, et al. Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010; 77: 922-930.
28. Dekkers R, Vijftigschild LA, Vonk AM, et al. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros 2015; 14: 178-181.
29. Walker LC, Venglarik CJ, Aubin G, et al. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med 1997; 155: 1684-1689.
30. Naren AP, Cobb B, Li C, et al. A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proc Natl Acad Sci USA 2003; 100: 342-346.
31. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6: 445-455.
32. Boyle MP, Diener-West M, Milgram L, et al. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 2003; 124: 482-489.
33. Rowe SM, Liu B, Hill A, et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One 2013; 8: e66955.
34. Knowles M, Gatzy J, Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 1983; 71: 1410-1417.
35. Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983; 221: 1067-1070.
36. Qadri YJ, Rooj AK, Fuller CM. ENaCs and ASICs as therapeutic targets. Am J Physiol Cell Physiol 2012; 302: C943-C965.
37. Iovannisci D, Illek B, Fischer H. Function of the HVCN1 proton channel in airway epithelia and a naturally occurring mutation, M91T. J Gen Physiol 2010; 136: 35-46.
38. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2005; (4): CD003428.
39. Reddy MM, Quinton PM. PKA mediates constitutive activation of CFTR in human sweat duct. J Membr Biol 2009; 231: 65-78.
40. Reddy MM, Quinton PM. cAMP activation of CF-affected Cl-conductance in both cell membranes of an absorptive epithelium. J Membr Biol 1992; 130: 49-62.